A Q4/11 net loss of $2.8M, or $0.07 per share Read more…
ASTM has completed a $40M private placement with Eastern Capital Limited in a financing structured and arranged by MLV & Co. Read more…
ASTM develops autologous cellular therapies for the treatment of severe and chronic cardiovascular diseases. Read more…
Aastrom Biosciences (ASTM) develops autologous cellular therapies for the treatment of severe and chronic cardiovascular diseases. Read more…
Shares of ASTM trade to the upside … even … in anticipation … Read more…
Valuation versus Share Pricing Read more…
A net loss of $1.9M, or $0.05 per share Read more…
Tuesday, 11/8/11 at 4:30 pm (EST) @ http://www.aastrom.com Read more…
ASTM has been granted a key composition of matter patent for Ixmyelocel-T from the EU Patent Office. Read more…
The IMPACT-DCM clinical trial for ixmyelocel-T showed that treatment was well-tolerated and that efficacy observations were consistent Read more…
Founder and Director of Research, Henry McCusker enters his tenth (10) year at Scimitar Equity with past experience in sell-side analysis, buy-side management, corporate management and due diligence.